Loading...
OTCM
CHGCY
Market cap89bUSD
Dec 04, Last price  
27.06USD
1D
2.50%
1Q
21.62%
Name

Chugai Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
OTCM:CHGCY chart
P/E
17.84
P/S
5.90
EPS
235.35
Div Yield, %
—
Shrs. gr., 5y
0.01%
Rev. gr., 5y
11.27%
Revenues
1.17t
+5.33%
327,155,000,000326,098,000,000344,807,000,000326,938,000,000428,947,000,000379,509,000,000373,516,000,000391,220,000,000423,652,000,000461,109,000,000498,839,000,000491,780,000,000534,199,000,000579,787,000,000686,184,000,000786,946,000,000999,759,000,0001,259,946,000,0001,111,367,000,0001,170,611,000,000
Net income
387.32b
+19.00%
53,632,000,00038,417,000,00040,060,000,00039,265,000,00056,634,000,00041,433,000,00035,234,000,00048,205,000,00050,895,000,00050,980,000,00061,125,000,00053,592,000,00072,713,000,00092,488,000,000157,560,000,000214,733,000,000302,995,000,000374,429,000,000325,472,000,000387,317,000,000
CFO
447.60b
+9.19%
64,663,000,00040,538,000,00060,364,000,00039,277,000,00066,461,000,00015,572,000,00069,593,000,00077,299,000,00053,521,000,00037,034,000,00062,918,000,00038,787,000,000107,623,000,000119,074,000,000206,641,000,000205,035,000,000279,626,000,000244,112,000,000409,925,000,000447,600,000,000
Dividend
Dec 28, 20230.12297 USD/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
URL
https://www.chugai-pharm.co.jp/
IPO date
Mar 03, 1956
Employees
7,771
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT